Non-biologic DMARDs Research Articles

SAT0305 Costs of Best Supportive Care in the Treatment of Moderate-To-Severe Psoriatic Arthritis in the United States

BackgroundPsoriatic arthritis (PsA) is an inflammatory condition of the joints that occurs in up to 30% of patients with psoriasis. While the cost of DMARD therapy has previously been described,...

THU0499 Patient’s Adherence to Mixed DMARD (Biological and Non-Biological) Therapy

BackgroundAdherence is defined as the extent to which the patient continues the agreed-upon mode of treatment under limited supervision when faced with conflicting demands. Adding a biological agent to a...

AB0423 The threshold of pain in patients affected by rheumatoid arthritis correlates with ESR but not with ultrasound score

BackgroundIn clinical practice, joint synovitis is generally assessed indirectly, by collecting clinical and laboratory data. Ultrasound is a non-expensive, repeteable, non-invasive test and may help the clinician to monitor the...

SAT0469 Factors associated with work status and missed work days in rheumatoid arthritis

BackgroundWorking age patients with rheumatoid arthritis (RA) often struggle to maintain their physical functioning and ability to work outside the home due to the impact of chronic joint inflammation and...

THU0164 Polymorphism of Cytotoxic T-Lymphocyte Antigen 4 +49A/G is Associated with Refractoriness to Non-Biological Dmards in Rheumatoid Arthritis Patients

BackgroundThe value of genetics markers to predict non-responders to traditional DMARDs who are in need of biological therapy has not been studied so far in rheumatoid arthritis (RA).ObjectivesTo investigate whether...

THU0144 Induction of remission and inhibition of joint damage in patients with rheumatoid arthritis treated with mono- or combination therapy using non-biological DMARDS in routine clinical practice

BackgroundRecently, a tight control strategy with treat to target (T2T) is this worldwide to achieve remission, and to inhibit joint damage, in rheumatoid arthritis (RA) patients. However, little is known...

AB0495 Functional outcome in response to treatment with dmards compared to anti-TNF agents in a cohort with rheumatoid arthritis

BackgroundPatient focussed therapy in rheumatoid arthritis should meet the needs of the patients. From the perspective of the patient with rheumatoid arthritis control of symptoms and the prevention of disability...

SAT0046 Should there be Different Disease Activity Criteria for Assessment of Patients with Rheumatoid Arthritis According to Ethnic Backgrounds?

BackgroundPrevious studies on RA features between different ethnic groups have mainly focused on disability and disease activity scores, structural damage, genetic factors and health inequalities. However, data on RA distribution...

AB0438 Clinical features of pneumocystis pneumonia in patients with rheumatoid arthritis, in comparison with pneumocystis pneumonia in acquired immunodeficiency syndrome

BackgroundPneumocystis pneumonia (PCP) is rare, but life-threatening complications in patients with rheumatoid arthritis (RA). PCP in RA exhibits differently from PCP in acquired immunodeficiency syndrome (AIDS).ObjectivesThe aim of this study...

THU0217 Safety of Infliximab Therapy in HbsAg Carriers with Rheumatoid Arthritis: A Prospective Study

BackgroundPrevalence rate of hepatitis B virus (HBV) infection in China (13%) and many other developing countries are much higher than that in developed countries. When anti-TNF agents are more available...

THU0074 Different risk factors are associated with serious infection in rheumatoid arthritis patients with and without pulmonary comorbidities; Analyses from the real database

BackgroundPulmonary comorbidity (PC) is a clinically important complication in patients with rheumatoid arthritis (RA) because PC has been recognized as one of the prognostic factors for RA1-3 and often prevents...

FRI0366 Dmard use in the treatment of juvenile idiopathic arthritis: A cross-sectional analysis of the childhood arthritis and rheumatology research alliance (CARRA) registry

BackgroundThere have been fundamental changes in the treatment of juvenile idiopathic arthritis (JIA) over the last decade, including the introduction and widespread use of biologic DMARDs. However, the utilization of...

SAT0114 Effects Of Tocilizumab (TCZ) in Combination with Non-Biologic Dmards in the Inhibition of Progression of Synovitis, Bone Marrow Edema and Erosions Evaluated by Extremity-Dedicated Magnetic Resonance Imaging (MRI) In Rheumatoid Arthritis (RA)

BackgroundExtremity-dedicated MRI is a sensitive method to detect early inflammatory and destructive changes in peripheral joints of RA patients, while reducing costs and decreasing patient’s discomfort.ObjectivesThe objective of this phase...

FRI0385 Long term follow-up after systemic sclerosis patients treated with intravenous cyclophosphamide pulse therapy for interstitial lung disease: a single eustar center (042) experience.

BackgroundTwo RCT and several open-labeled studies demonstrated various efficacy of cyclophosphamide (CYC) for treatment of Systemic sclerosis-associated interstitial lung disease (SSc-ILD) with follow up for 1-4 years.ObjectivesTo analyze the changes...

AB0675 First episode of chronic anterior uveitis in patients with juvenile idiopathic arthritis and relationship with administered treatments

BackgroundChronic anterior uveitis is one of the most serious complications of juvenile idiopathic arthritis (JIA), showing an increased incidence in patients with early-onset disease, oligoarticualar, positive ANA. Biologic therapy used...

OP0302 Moderate to High Disease Activity in Psoriatic Arthritis is Associated with Elevated Total Cholesterol and Triglycerides

BackgroundPsoriatic arthritis (PsA) is associated with a higher frequency of abnormal lipids and obesity compared with healthy controls and rheumatoid arthritis. There is also an increased risk of developing PsA...

OP0250 Exploration of omeract preliminary rheumatoid arthritis (RA) flare domains in a longitudinal observational study

BackgroundThe word “flare” is often used to describe episodes of disease worsening in RA, but no established definition of flare in RA currently exists. The OMERACT RA Flare Group has...

OP0167 Acute Myocardial Infarction is Driven by Chronic Systemic Inflammation, Irrespective of the Kind of Treatment - Data from the German Biologics Register Rabbit

BackgroundRheumatoid arthritis is associated with increased cardiovascular morbidity and mortality including acute myocardial infarction (AMI). Chronic systemic inflammation and accelerated atherosclerosis contribute to this risk. In daily practice, RA-patients with...

AB1343 Impact of a rheumatoid arthritis multi-biomarker disease activity test on clinical practice

BackgroundAssessment of disease activity in patients with RA includes patient and physician reported measures and differs by rheumatologist and practice, resulting in variability in treatment decisions and quality of care....

FRI0529 Comparative risks for serious infections associated with biologics in high risk rheumatoid arthritis patients

BackgroundSerious infections are an important concern for patients with rheumatoid arthritis (RA) treated with biologic agents. However, insufficient data guide the optimal treatment in the high risk population.ObjectivesTo compare the...